Introduction {#S1}
============

Neurodegenerative diseases (NDDs), such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD), are prevalent and incredibly devastating diseases, with an estimated 6 million people affected by NDDs in the United States alone. A common risk factor for most NDDs is advancing age, and with a globally growing elderly population, the number of cases is expected to increase rapidly worldwide in the coming years. Substantial efforts have been undertaken to study NDDs, which have led to fundamental insights into these diseases. Still, the neurobiology that underlies NDDs is not well understood. With limited knowledge, therapeutic interventions have been developed to delay deterioration and provide temporary relief of symptoms, but there remains a tremendous need to improve treatments.

Although NDDs uniquely affect specific neuronal subpopulations, the accumulation of distinct protein-based macroscopic deposits that cause neuronal loss is a common hallmark of NDDs. In parallel with progressive neuronal loss, synaptic dysfunction, altered calcium homeostasis, aberrant neural activity, abnormal neuronal plasticity, and impairment in large-scale neural circuits are well-documented features of many NDDs ([@B83]; [@B33]; [@B88]; [@B50]). The interdependence between abnormal protein depositions, neuronal loss, and dysfunctional neural networks remains to be determined. Nevertheless, growing evidence suggests that many neurological deficits in NDDs may reflect functional impairment in neural circuits rather than neuronal loss ([@B81]; [@B107]), suggesting that targeting reversible neural circuits holds therapeutic potential and deserves substantial consideration ([@B56]; [@B8]; [@B16]).

Due to technical challenges in performing longitudinal studies on individual neurons in large-scale populations from subcortical brain regions in freely moving animals, our current understanding of the neural circuit mechanisms that underlie NDDs and associated symptoms remains limited. In the present mini-review, we focus on the potential of the miniature fluorescence microscope (miniscope), a recently developed *in vivo* calcium imaging technology ([Figure 1](#F1){ref-type="fig"}; [@B2]), to provide new insights into dysfunctional neural circuits that contribute to the pathogeneses of NDDs. We first discuss a brief history of the miniscope, and then describe specific capabilities of the miniscope with potential applications to study microcircuit dysfunction in models of NDDs.

![The miniscope. **(A)** Basic components of miniScope and GRIN lens system. **(B)** Schematic for a mounted miniScope with the GRIN lens aimed at GECI-labeled cells in a deep brain structure. GRIN, gradient index lens; GECI, genetically encoded calcium indicator.](fnins-13-01174-g001){#F1}

A Brief History of the Miniscope {#S2}
================================

The observation of *in vivo* calcium transients using microscopy would not be possible without calcium indicators ([@B36]). Genetically encoded calcium indicators (GECIs; [@B77]), and GCaMP-family GECIs in particular ([@B78]; [@B117]; [@B18]), have proved to be incredibly important tools, and have played important roles in defining what can be achieved with calcium imaging. Ongoing advancements in calcium sensors continue to push beyond current limitations, and with activity sensors also moving beyond calcium, voltage, neurotransmitter, and ion sensors will help to shape a very different future for fluorescence microscopy ([Table 1](#T1){ref-type="table"}; [@B63]; [@B27]).

###### 

Selected genetically encoded indicators.

  **Type**        **Sensor examples**   **Reference**
  --------------- --------------------- ---------------
  Calcium         GCaMP6                [@B18]
                  GCaMP7                [@B25]
                  jRGECO1               [@B24]
                  XCaMPs                [@B49]
  Voltage         QuasAr2               [@B45]
                  ArcLight              [@B55]
  Dopamine        GRAB~DA~              [@B113]
                  dLight1               [@B87]
  Glutamate       SF-iGluSnFR           [@B69]
  Acetylcholine   GACh                  [@B53]
  Potassium       KIRIN1                [@B109]

Coinciding with advancements in fluorescent activity reporters has been progress in imaging instrumentation. Since the development of two-photon microscopy ([@B26]), studies examining calcium activity have increased dramatically. Imaging cortical activity through cranial windows in head-fixed animals using a variety of behaviors has provided many new insights into the neuronal encoding of behavior ([@B128]; [@B54]), and the emergence of Gradient Index (GRIN) lenses, which relay images from one end to the other to provide an optical interface to the brain, has allowed for endoscopic imaging of deep brain regions ([@B10]; [@B129]; [@B132]). Examination of neuronal activity during behavior in freely moving animals was then made possible by the development of fiber-optic based microscopes ([@B42], [@B41]; [@B32]; [@B102]) and miniature fluorescence microscopes with two-photon ([@B42]; [@B102]; [@B61]; [@B135]) or epifluorescent light sources ([@B34]).

The first miniscope was developed by [@B34], which included a number of unique features. The miniscope was head-mounted with fluorescence excitation and detection onboard rather than away from the microscope, and also bypassed cost limitations of table-top setups by using commercially available and inexpensive technologies. The miniscope offers many unique advantages, including the ability to perform recordings that are cell-type specific, large-scale (hundreds of cells can be recorded), and longitudinal in nature \[cells can be recorded for months ([@B132])\]. These features provide a unique tool to study NDDs, as the miniscope can image cells in microcircuits during the development of NDD-like pathophysiology and behavior in animal models.

*In Vivo* Deep Brain Imaging in Freely Moving Animals {#S3}
=====================================================

Many behavioral manifestations of NDDs have been modeled in animals ([@B35]), and understanding the microcircuitry that encodes disease-related aberrant behaviors could provide essential insights into the neurobiology underlying NDDs. However, observing neuronal activity during behaviors in freely moving animals has been technically challenging. Two-photon imaging using table-top setup approaches requires head fixation, which limits the usability to certain behavioral assays. Moreover, differences in neural activity have been reported in head-fixed animals compared to freely moving animals, suggesting that head-restrained and natural conditions have different neural correlates ([@B94]; [@B1]). Various instruments have been developed to examine neuronal activity during behavior in freely moving animals ([@B42], [@B41]; [@B32]; [@B102]; [@B61]; [@B135]), but the miniscope offers a unique option that is accessible, compact, and affordable ([Figure 1](#F1){ref-type="fig"} and [Table 2](#T2){ref-type="table"}; [@B2]).

###### 

Open-source miniscopes.

  **Miniscope**    **Developer**           **Platform**                                          **Reference**
  ---------------- ----------------------- ----------------------------------------------------- ---------------
  UCLA miniscope   UCLA                    <http://miniscope.org/index.php/Main_Page>            [@B15]
  FinchScope       Boston University       <https://github.com/gardner-lab/FinchScope>           [@B62]
  miniScope        NIDA                    <https://github.com/giovannibarbera/miniscope_v1.0>   [@B9]
  CHEndoscope      University of Toronto   <https://github.com/jf-lab/chendoscope>               [@B51]
  cScope           Princeton               <https://github.com/PrincetonUniversity/cScope>       [@B106]

An additional technical challenge is accessing deep brain structures that are preferentially affected in many NDDs. Until recently, the ability of fluorescence microscopy to monitor neuron activity at subcellular resolution has been limited to superficial depths of ∼1 mm ([@B76]). This is due to light scattering that occurs in tissue ([@B52]), as well as tissue damage and inflammatory responses that occurs when removing overlaying tissue to provide optical access to a structure of interest. Imaging neurons in deeper brain structures is more practical with endoscopic techniques, which include insertion of lenses into the brain. The use of smaller-diameter GRIN lenses can reduce tissue damage ([@B12]; [@B129]) and minimize the effect on behavior ([@B57]), which can be further improved with the use of robotic surgical instruments ([@B59]).

Longitudinal Tracking of Individual Cells to Study Ndds {#S4}
=======================================================

Aging is a leading risk factor for many NDDs. While each NDD demonstrates unique spatiotemporal patterns of degeneration, the often-slow advancement of these diseases provides a similarly distinct challenge for researchers to study. A major cause of age-related degeneration is the accumulation of disease-specific misfolded proteins that lead to progressive loss of neuronal function ([@B47]; [@B19]). However, changes in patterned neural and circuit activity have also been observed in most NDDs and are believed to contribute to the onset and progression of disease states ([@B81]; [@B107]).

Hyperexcitability in Early Stage of NDDs {#S4.SS1}
----------------------------------------

Hyperexcitability has been observed in a number of NDDs. Cortical and peripheral hyperexcitability has been well-documented in clinical studies of ALS patients ([@B75]; [@B123]; [@B124]; [@B126]; [@B72]), and is among the earliest pathologies identified in ALS patients ([@B6]) and during early stages of ALS-like pathology in rodent models ([@B118]; [@B133]; [@B66]). Therefore, it is presumed that neuronal hyperexcitability is an important factor that leads to neuronal loss in ALS. In AD, although hypoactivity is a key feature of late stages of the disease ([@B13]; [@B79]), paradoxical hyperactivity has been observed in multiple brain regions of AD patients during pre-symptomatic stages ([@B110]; [@B28]; [@B74]; [@B90]; [@B130]). Furthermore, chronic aberrant increases in excitatory neuronal activity have been detected in the hippocampal and cortical regions in AD mouse models ([@B82]; [@B14]), and increasing neural activity has been demonstrated to directly promote the production and secretion of amyloid-β (Aβ) peptide ([@B22], [@B21]; [@B11]), whose excessive accumulation appears to play a causal role in AD ([@B112]). However, how hyperexcitable neurons encode behavior and contribute to disease progression remains unknown.

Therapeutic Potential of Targeting Hyperactivity {#S4.SS2}
------------------------------------------------

Targeting hyperactivity in mouse models of AD and ALS has been demonstrated to improve signatures of neural injury ([@B100]; [@B131]; [@B133]; [@B37]), and, importantly, clinical trials aiming to reduce hippocampal hyperactivity showed positive effects in patients with amnestic cognitive impairment ([@B8]). The most widely prescribed drug for ALS, riluzole, reduces excitatory synaptic activity in the brain ([@B29]), and memantine, a therapeutic drug approved for use in late-stage AD, functions as a NMDA receptor antagonist to counteract hyperactive glutamatergic circuits ([@B134]). But still, there remains a need to determine how these drugs affect neuronal activity to provide therapeutic relief to disease-related behavioral symptoms. Examining the activity of individual neurons across time could provide insights into how microcircuits encode pathophysiological behaviors as diseases advance. The miniscope is able to track individual neurons for several months during behaviors in freely moving animals ([@B60]; [@B132]), providing an opportunity to examine how changes in activity in individual neurons within a microcircuit across long periods of time affect behavior.

Imaging Specific Cellular Subtypes to Study Ndds {#S5}
================================================

Each NDD has a signature pattern of degeneration progression. Particular circuits are vulnerable, and specific subtypes of cells within circuit-associated brain regions are targeted. In combination with transgenic rodent lines and/or cell-type specific and inducible promotors for vectors in gene therapy, specific neuron subtypes, and other cell-types in the brain can be imaged with the miniscope. This capability provides exciting opportunities for new insights into how neuronal subtypes encode pathology-related behaviors in models of NDDs.

Imaging Dopaminergic, Cholinergic, and Medium Spiny Neurons {#S5.SS1}
-----------------------------------------------------------

The manifestation of PD symptoms is believed to be the cause of dopaminergic neuron loss in the substantia nigra pars compacta (SNc) that leads to an imbalance in basal ganglia direct and indirect pathways ([@B71]). Studies with parkinsonian rodents have linked activity changes to discrete neuronal populations with potentially distinct contributions to and/or alleviation of parkinsonian motor symptoms ([@B65]; [@B86]; [@B98]; [@B99]). Using transgenic Cre-driver mouse lines and a commercial miniscope, [@B86] reported that medium spiny neurons (MSNs) in the direct and indirect pathways displayed bidirectional changes in firing rate in parkinsonian mice. Firing rates in MSNs, along with behavioral abnormalities, were reversed by administration of L-DOPA or a dopamine receptor D~2~ receptor agonist ([@B86]). While this study demonstrated some of the capabilities of miniscope imaging, numerous questions still remain related to firing rate, pattern, and synchronization of neurons in the SNc and other brain regions that are believed to contribute to PD pathology.

Selective vulnerability of MSNs in the basal ganglia is a characteristic of HD ([@B97]). MSNs are unique in that they not only receive dopaminergic input from the midbrain but also glutamatergic input from the cortex and other brain regions. Direct imaging of MSN activity in the basal ganglia would provide useful clues to determine intrinsic properties of MSNs that may lead to vulnerability in HD.

Neuromodulatory system dysfunction has been linked to a number of NDDs, but how specific neuromodulatory systems encode behavior in models of NDD has yet to be examined. Selective loss of cholinergic neurons have been observed in postmortem brains of AD patients ([@B125]; [@B73]), and reductions in cholinergic markers are strongly correlated with cognitive decline in PD patients ([@B89]). Importantly, clinical studies support beneficial effects of cholinesterase inhibitor treatment in both PD and AD patients ([@B31]; [@B134]), suggesting a need to better understand how cholinergic neuron dysfunction contributes to symptoms in PD, AD, and other NDDs.

Imaging Specific Inhibitory Interneurons {#S5.SS2}
----------------------------------------

γ-aminobutyric acid (GABA) plays a central role in regulating neuronal excitability and maintaining balanced network activity, and inhibitory interneuron abnormalities also contribute to a number of NDDs. Inhibitory interneuron dysfunction has been suggested to contribute to network hypersynchrony ([@B83]) that underlies frequent epileptic activity that occurs in AD patients ([@B121], [@B122]), as deficits in inhibitory interneurons result in impaired oscillatory rhythm and network hyperactivity in AD mouse models ([@B7]; [@B120]; [@B119]; [@B39]). In addition, reductions of subpopulations of inhibitory interneurons have been described in AD mouse models and postmortem brains of AD patients ([@B93]; [@B114]; [@B3]; [@B64]). Dysfunctional interneurons have also been linked to upper motor neuron hyperexcitability in an ALS/FTD model ([@B133]). Imbalance of excitation-to-inhibition (E/I) due to interneuron impairment has been suggested to be a potential common driver for AD and ALS, as well as other NDDs ([@B30]; [@B4]). Studies on inhibitory interneurons using miniscope imaging in NDD models could shed light on this theory and provide information on inhibitory interneurons in NDD pathogenesis.

Imaging Specific Glial Cells {#S5.SS3}
----------------------------

A variety of glial cells have complex reciprocal interactions with neurons to support their functions and are active participants in neural circuit refinement ([@B84]; [@B103]; [@B95]; [@B115]). For instance, subsets of astrocytes in the basal ganglia release glutamate to selectively activate homotypic synapses to regulate neural networks ([@B67]). Dysfunctional glial cells contribute to the disease progression in both HD and ALS through non-cell-autonomous toxicity ([@B127]; [@B38]; [@B23]). Neuroinflammation that results from chronic activation of immune responses are often mediated by microglia and occur in susceptible regions, and are believed to contribute to age-related degeneration ([@B70]; [@B17]). Microglial activation and reactive astrogliosis are observed in many NDDs, and reactive astrocytes lose many normal functions and gain new abnormal functions. Synapse elimination by microglial and astrocytes may contribute to the loss of presynaptic terminals and dendritic spines ([@B20]; [@B43]), one of the earliest features associated with cognitive impairment in many NDDs ([@B116]; [@B104]). Glial cells may selectively remove excitatory or inhibitory synapses to compensate for disease-associated changes at specific brain regions ([@B46]; [@B5]; [@B85]), or may act as a primary driver for the E/I imbalance by directly inducing excessive synaptic pruning ([@B108]; [@B96]). Studying glial activity though miniscope calcium imaging might provide useful information on the mechanism of how glial dysfunctions contribute to NDDs.

New Frontiers in Miniscope Imaging {#S6}
==================================

The current generation of miniscopes offers many exciting possibilities for the study of NDDs. Innovation of the miniscope has been dramatically accelerated by open-source sharing of miniscope projects ([Table 2](#T2){ref-type="table"}; [@B2]), with functional improvements that hold the promise of new frontiers. The next generation of miniscopes and fluorescence sensors boast capabilities to distinguish two neuron subtypes simultaneously, manipulate cellular activity while imaging, image cellular events with non-calcium indicators, and record electrical properties ([@B27]; [@B2]).

GECIs With Spectrally Separable Wavelengths {#S6.SS1}
-------------------------------------------

In the case of NDDs, it would be advantageous to simultaneously image a preferentially affected cell-type population, as those described above, while also imaging surrounding cell-types. This would provide information to understand how dysfunction of a vulnerable cellular population not only affects behavior, but also the other cells in the local microcircuit. Development of GECIs ([Table 1](#T1){ref-type="table"}) with spectrally separable wavelengths ([@B18]; [@B24]; [@B49]) provide potential to examine the concomitance of two distinct neuronal populations correlated to specific behaviors, which can be accomplished a number of ways, including using a Cre-On/Cre-off approach ([@B101]).

GECIs with distinct wavelengths also provide an opportunity to concurrently image and manipulate neural activity. Miniscope imaging offers correlational insight into neural activity that encodes behavior, but manipulating neural activity concurrently with imaging can offer insight into causal roles of cell populations within microcircuits ([@B111]). This task can be achieved by using light-driven channels that have minimal overlapping spectra with a fluorescent activity sensor. One could also model dysregulated neuronal firing observed in NDDs with optogenetics while recording surrounding neuron activity during behavior.

Non-calcium Fluorescence Activity Sensors {#S6.SS2}
-----------------------------------------

Fluorescence imaging has focused primarily on measuring intracellular calcium transients. However, florescent sensors for dopamine transients ([@B87]; [@B113]), glutamate transients ([@B68], [@B69]), intracellular potassium ion concentration ([@B109]) and voltage signals ([@B63]; [@B27]), among others, have been developed for imaging ([Table 1](#T1){ref-type="table"}), with more to come. Many NDDs feature a variety of aberrant signaling, including dysfunction of dopamine and glutamate ([@B40]; [@B48]; [@B58]; [@B105]; [@B91]), which provides an abundance of opportunities to study NDDs with these cutting-edge sensors. For example, dopamine sensors could be used to image dopamine transients in the SNc during progressive loss of dopaminergic neurons.

Extensive evidence suggests that many NDDs may be characterized by alterations in single-cell firing patterns and dyssynchronization between circuit nodes. Electrophysiological techniques currently offer unparalleled temporal resolution, but are unable to record spatiotemporal dynamics of action potential activity in ensembles with single-neuron resolution ([@B44]; [@B80]). Fluorescence imaging infers neural activity with high sensitivity but is traditionally unable to accurately resolve individual action potentials during high frequency firing due to slow decays. Engineering of voltage-responsive fluorophores is advancing rapidly with hopes of providing fluorescence responses that can greatly improve temporal resolution ([@B27]; [@B92]).

Conclusion {#S7}
==========

Capable of performing cell-type specific recordings on large-scale populations longitudinally, the miniscope offers opportunities to ask new and exciting questions in NDDs. Studies utilizing miniscope imaging are increasing rapidly across disciplines of neuroscience but are not commonly being used in NDD models. It is our hope that this mini-review, while by no means exhaustive, brings attention to the powerful capabilities of miniscope imaging, and offers a glimpse into potential questions that could be answered with miniscope experiments in studies of NDDs.
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